Technology
Health
Pharmaceutical

Ironwood Pharmaceuticals

$13.69
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (0.44%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IRWD and other stocks, options, ETFs, and crypto commission-free!

About

Ironwood Pharmaceuticals, Inc. Class A Common Stock, also called Ironwood Pharmaceuticals, is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Read More Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller in 1998 and is headquartered in Cambridge, MA.

Employees
515
Headquarters
Cambridge, Massachusetts
Founded
1998
Market Cap
2.10B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.34M
High Today
$13.95
Low Today
$13.62
Open Price
$13.65
Volume
337.76K
52 Week High
$21.20
52 Week Low
$9.07

Collections

Technology
Health
Pharmaceutical
Biotechnology
US
North America

News

Yahoo FinanceMar 16

Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we’ll take a look at whether insiders have been buying or selling shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). What Is Insider Buying? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. Ho...

22
Yahoo FinanceMar 15

Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. A month has gone by since the last earnings report for Ironwood Pharmaceuticals (IRWD). Shares have lost about 0.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Ironwood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the...

7
Yahoo FinanceMar 14

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- – “When-issued” trading of CYCN expected to begin on Nasdaq on March 18, 2019 – – Separation completion expected April 1, 2019 – Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is expec...

9

Earnings

-$0.38
-$0.26
-$0.14
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.